Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways
-
Published:2024-08
Issue:
Volume:177
Page:116952
-
ISSN:0753-3322
-
Container-title:Biomedicine & Pharmacotherapy
-
language:en
-
Short-container-title:Biomedicine & Pharmacotherapy
Author:
Yong Qiuhong,
Huang Chaoyuan,
Chen Bonan,
An Jinqi,
Zheng Yiyuan,
Zhao Lina,
Peng Chong,
Liu FengbinORCID
Reference45 articles.
1. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis;Anstee;Nat. Rev. Gastroenterol. Hepatol.,2013
2. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018
3. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat. Rev. Gastroenterol. Hepatol.,2018
4. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015;Mortality;Lancet,2016
5. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease;Angulo;Gastroenterology,2015